Galectin Therapeutics Inc. (NASDAQ:GALT)

CAPS Rating: 1 out of 5

A development stage pharmaceutical company engaged in the discovery, development and commercialization of carbohydrate-based therapeutic compounds for advanced treatment of cancer, liver, microbial, cardiovascular and inflammatory diseases.


Player Avatar pchop123 (79.82) Submitted: 2/25/2013 11:18:00 AM : Underperform Start Price: $3.48 GALT Score: -0.55

cash burn intensifying beyond the curtains

Featured Broker Partners